[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Ovarian Cancer Drugs Market Report 2017

August 2017 | 96 pages | ID: U40C0CB4996EN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Ovarian Cancer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Ovarian Cancer Drugs in these regions, from 2012 to 2022 (forecast).
United States Ovarian Cancer Drugs market competition by top manufacturers/players, with Ovarian Cancer Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • Roche
  • Boehringer Ingelheim
  • Celgene
  • Amgen
  • AstraZeneca
  • GlaxoSmithKline
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • By Therapy
    • Oral Therapy
    • Injectable Therapy
  • By Drugs
    • Cisplatin
    • Carboplatin
    • Taxol (Paclitaxel)
    • Topotecan Hydrochloride
    • Gemcitabine Hydrochloride
    • Doxorubicin Hydrochloride Liposome
    • Other
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Ovarian Cancer Drugs for each application, including
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Ovarian Cancer Drugs Market Report 2017

1 OVARIAN CANCER DRUGS OVERVIEW

1.1 Product Overview and Scope of Ovarian Cancer Drugs
1.2 Classification of Ovarian Cancer Drugs by Product Category
  1.2.1 United States Ovarian Cancer Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Ovarian Cancer Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Oral Therapy
  1.2.4 Injectable Therapy
1.3 United States Ovarian Cancer Drugs Market by Application/End Users
  1.3.1 United States Ovarian Cancer Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Chemotherapy
  1.3.3 Targeted Therapy
  1.3.4 Immunotherapy (Biologic Therapy)
1.4 United States Ovarian Cancer Drugs Market by Region
  1.4.1 United States Ovarian Cancer Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Ovarian Cancer Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Ovarian Cancer Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Ovarian Cancer Drugs Status and Prospect (2012-2022)
  1.4.5 New England Ovarian Cancer Drugs Status and Prospect (2012-2022)
  1.4.6 The South Ovarian Cancer Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Ovarian Cancer Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Ovarian Cancer Drugs (2012-2022)
  1.5.1 United States Ovarian Cancer Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Ovarian Cancer Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES OVARIAN CANCER DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Ovarian Cancer Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Ovarian Cancer Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Ovarian Cancer Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Ovarian Cancer Drugs Market Competitive Situation and Trends
  2.4.1 United States Ovarian Cancer Drugs Market Concentration Rate
  2.4.2 United States Ovarian Cancer Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Ovarian Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES OVARIAN CANCER DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Ovarian Cancer Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Ovarian Cancer Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Ovarian Cancer Drugs Price by Region (2012-2017)

4 UNITED STATES OVARIAN CANCER DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Ovarian Cancer Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Ovarian Cancer Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Ovarian Cancer Drugs Price by Type (2012-2017)
4.4 United States Ovarian Cancer Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES OVARIAN CANCER DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Ovarian Cancer Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Ovarian Cancer Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES OVARIAN CANCER DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Roche
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Ovarian Cancer Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Roche Ovarian Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Boehringer Ingelheim
  6.2.2 Ovarian Cancer Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Boehringer Ingelheim Ovarian Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Celgene
  6.3.2 Ovarian Cancer Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Celgene Ovarian Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Amgen
  6.4.2 Ovarian Cancer Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Amgen Ovarian Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 AstraZeneca
  6.5.2 Ovarian Cancer Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 AstraZeneca Ovarian Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 GlaxoSmithKline
  6.6.2 Ovarian Cancer Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 GlaxoSmithKline Ovarian Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview

7 OVARIAN CANCER DRUGS MANUFACTURING COST ANALYSIS

7.1 Ovarian Cancer Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Ovarian Cancer Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Ovarian Cancer Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Ovarian Cancer Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Ovarian Cancer Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Ovarian Cancer Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Ovarian Cancer Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Ovarian Cancer Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Ovarian Cancer Drugs
Figure United States Ovarian Cancer Drugs Market Size (MT) by Type (2012-2022)
Figure United States Ovarian Cancer Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Oral Therapy Product Picture
Figure Injectable Therapy Product Picture
Figure United States Ovarian Cancer Drugs Market Size (MT) by Application (2012-2022)
Figure United States Sales Market Share of Ovarian Cancer Drugs by Application in 2016
Figure Chemotherapy Examples
Table Key Downstream Customer in Chemotherapy
Figure Targeted Therapy Examples
Table Key Downstream Customer in Targeted Therapy
Figure Immunotherapy (Biologic Therapy) Examples
Table Key Downstream Customer in Immunotherapy (Biologic Therapy)
Figure United States Ovarian Cancer Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Ovarian Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Ovarian Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Ovarian Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Ovarian Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Ovarian Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Ovarian Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Ovarian Cancer Drugs Sales (MT) and Growth Rate (2012-2022)
Figure United States Ovarian Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Ovarian Cancer Drugs Market Major Players Product Sales Volume (MT) (2012-2017)
Table United States Ovarian Cancer Drugs Sales (MT) of Key Players/Suppliers (2012-2017)
Table United States Ovarian Cancer Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Ovarian Cancer Drugs Sales Share by Players/Suppliers
Figure 2017 United States Ovarian Cancer Drugs Sales Share by Players/Suppliers
Figure United States Ovarian Cancer Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Ovarian Cancer Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Ovarian Cancer Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Ovarian Cancer Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Ovarian Cancer Drugs Revenue Share by Players/Suppliers
Table United States Market Ovarian Cancer Drugs Average Price (K USD/Kg) of Key Players/Suppliers (2012-2017)
Figure United States Market Ovarian Cancer Drugs Average Price (K USD/Kg) of Key Players/Suppliers in 2016
Figure United States Ovarian Cancer Drugs Market Share of Top 3 Players/Suppliers
Figure United States Ovarian Cancer Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Ovarian Cancer Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Ovarian Cancer Drugs Product Category
Table United States Ovarian Cancer Drugs Sales (MT) by Region (2012-2017)
Table United States Ovarian Cancer Drugs Sales Share by Region (2012-2017)
Figure United States Ovarian Cancer Drugs Sales Share by Region (2012-2017)
Figure United States Ovarian Cancer Drugs Sales Market Share by Region in 2016
Table United States Ovarian Cancer Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Ovarian Cancer Drugs Revenue Share by Region (2012-2017)
Figure United States Ovarian Cancer Drugs Revenue Market Share by Region (2012-2017)
Figure United States Ovarian Cancer Drugs Revenue Market Share by Region in 2016
Table United States Ovarian Cancer Drugs Price (K USD/Kg) by Region (2012-2017)
Table United States Ovarian Cancer Drugs Sales (MT) by Type (2012-2017)
Table United States Ovarian Cancer Drugs Sales Share by Type (2012-2017)
Figure United States Ovarian Cancer Drugs Sales Share by Type (2012-2017)
Figure United States Ovarian Cancer Drugs Sales Market Share by Type in 2016
Table United States Ovarian Cancer Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Ovarian Cancer Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Ovarian Cancer Drugs by Type (2012-2017)
Figure Revenue Market Share of Ovarian Cancer Drugs by Type in 2016
Table United States Ovarian Cancer Drugs Price (K USD/Kg) by Types (2012-2017)
Figure United States Ovarian Cancer Drugs Sales Growth Rate by Type (2012-2017)
Table United States Ovarian Cancer Drugs Sales (MT) by Application (2012-2017)
Table United States Ovarian Cancer Drugs Sales Market Share by Application (2012-2017)
Figure United States Ovarian Cancer Drugs Sales Market Share by Application (2012-2017)
Figure United States Ovarian Cancer Drugs Sales Market Share by Application in 2016
Table United States Ovarian Cancer Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Ovarian Cancer Drugs Sales Growth Rate by Application (2012-2017)
Table Roche Basic Information List
Table Roche Ovarian Cancer Drugs Sales (MT), Revenue (Million USD), Price (K USD/Kg) and Gross Margin (2012-2017)
Figure Roche Ovarian Cancer Drugs Sales Growth Rate (2012-2017)
Figure Roche Ovarian Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Roche Ovarian Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Boehringer Ingelheim Basic Information List
Table Boehringer Ingelheim Ovarian Cancer Drugs Sales (MT), Revenue (Million USD), Price (K USD/Kg) and Gross Margin (2012-2017)
Figure Boehringer Ingelheim Ovarian Cancer Drugs Sales Growth Rate (2012-2017)
Figure Boehringer Ingelheim Ovarian Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Boehringer Ingelheim Ovarian Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Celgene Basic Information List
Table Celgene Ovarian Cancer Drugs Sales (MT), Revenue (Million USD), Price (K USD/Kg) and Gross Margin (2012-2017)
Figure Celgene Ovarian Cancer Drugs Sales Growth Rate (2012-2017)
Figure Celgene Ovarian Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Celgene Ovarian Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Amgen Basic Information List
Table Amgen Ovarian Cancer Drugs Sales (MT), Revenue (Million USD), Price (K USD/Kg) and Gross Margin (2012-2017)
Figure Amgen Ovarian Cancer Drugs Sales Growth Rate (2012-2017)
Figure Amgen Ovarian Cancer Drugs Sales Market Share in United States (2012-2017)
Figure Amgen Ovarian Cancer Drugs Revenue Market Share in United States (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Ovarian Cancer Drugs Sales (MT), Revenue (Million USD), Price (K USD/Kg) and Gross Margin (2012-2017)
Figure AstraZeneca Ovarian Cancer Drugs Sales Growth Rate (2012-2017)
Figure AstraZeneca Ovarian Cancer Drugs Sales Market Share in United States (2012-2017)
Figure AstraZeneca Ovarian Cancer Drugs Revenue Market Share in United States (2012-2017)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Ovarian Cancer Drugs Sales (MT), Revenue (Million USD), Price (K USD/Kg) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Ovarian Cancer Drugs Sales Growth Rate (2012-2017)
Figure GlaxoSmithKline Ovarian Cancer Drugs Sales Market Share in United States (2012-2017)
Figure GlaxoSmithKline Ovarian Cancer Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Ovarian Cancer Drugs
Figure Manufacturing Process Analysis of Ovarian Cancer Drugs
Figure Ovarian Cancer Drugs Industrial Chain Analysis
Table Raw Materials Sources of Ovarian Cancer Drugs Major Players/Suppliers in 2016
Table Major Buyers of Ovarian Cancer Drugs
Table Distributors/Traders List
Figure United States Ovarian Cancer Drugs Sales Volume (MT) and Growth Rate Forecast (2017-2022)
Figure United States Ovarian Cancer Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Ovarian Cancer Drugs Price (K USD/Kg) Trend Forecast (2017-2022)
Table United States Ovarian Cancer Drugs Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Ovarian Cancer Drugs Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Ovarian Cancer Drugs Sales Volume (MT) Forecast by Type in 2022
Table United States Ovarian Cancer Drugs Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Ovarian Cancer Drugs Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Ovarian Cancer Drugs Sales Volume (MT) Forecast by Application in 2022
Table United States Ovarian Cancer Drugs Sales Volume (MT) Forecast by Region (2017-2022)
Table United States Ovarian Cancer Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Ovarian Cancer Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Ovarian Cancer Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories